The Princeton CDMO - formerly BioCentriq - built to carry living-cell therapies from the lab bench to commercial supply, without the handoffs that stall programs.
Most cell therapies fail not in the discovery lab but on the factory floor. The biology can be brilliant and the trial can be promising, yet the therapy never reaches patients because it cannot be made the same way twice, at the volume a market demands. Made Scientific, a contract development and manufacturing organization headquartered in Princeton, New Jersey, was built on that uncomfortable truth.
The company develops, manufactures, tests and releases cell therapy products - both autologous, made from a single patient's own cells, and allogeneic, produced from donor cells for many patients. It works across the full arc of a program: process and analytical development, GMP manufacturing, aseptic fill and finish, quality-control release testing, regulatory support and workforce training. The pitch is deliberately unglamorous. It handles the part of the value chain where therapies most often live or die.
Made Scientific is not a start-up in the usual sense. It began life as BioCentriq, a cell therapy CDMO founded in 2019, and was acquired by South Korea's GC Corporation, a global pharmaceutical and biotechnology group. In March 2025 the company rebranded to Made Scientific - shorthand, its leadership says, for manufacturing and development excellence - and paired the new name with a $12 million investment in its Princeton headquarters.
The rebrand was not cosmetic. Leadership had heard the same three complaints from clients across the industry: scalability is hard, vendors rarely flex, and manufacturing readiness is treated as an afterthought. Made Scientific set out to answer all three, and organized the company around them.
Made Scientific's clients are cell and gene therapy developers - biotech and pharmaceutical companies moving therapies from preclinical work toward the clinic and, ultimately, the market. Some arrive early, needing a process built from scratch. Others arrive late, needing commercial-scale capacity and a partner who can pass an FDA or EU inspection.
To meet them where they are, the company offers three ways to work: a traditional service model, a hybrid "client-in-plant" arrangement where a customer's own staff operate inside the facility, and fully custom build-outs. Flexibility, in other words, is treated as a product feature rather than a favor.
Autologous therapy leaves no room for error. When a batch is made from one patient's cells, there is no second batch to fall back on. That single fact reshapes everything: closed-system processing, rigorous batch records, cold-chain logistics and QC release testing stop being paperwork and become the product itself.
The industry also faces a quieter shortage - people. Experienced cell therapy operators are scarce because the field is young. Made Scientific responds with the Made Foundry, an in-house training program designed to build the workforce it cannot simply hire.
The same themes emerged again and again: scalability is a challenge, vendor flexibility is rare, and manufacturing readiness is often an afterthought.
Manufacturing process design and validated analytical methods that prepare programs for GMP production and regulatory filings.
Integrated drug substance and drug product manufacturing for autologous and allogeneic therapies.
Automated aseptic filling and finishing built toward EU Annex 1 standards.
In-house quality control, potency and identity assays, and stability studies supporting batch release.
Pathway planning, submissions support and compliance for US FDA and EU markets.
Structured training programs building the cell therapy manufacturing talent the industry is short on.
The largest CDMOs - Lonza, Catalent, Charles River, WuXi - offer scale and a broad menu. Made Scientific bets instead on being a focused specialist: cell therapy only, with development, manufacturing and QC under one roof to shorten timelines and reduce the handoffs where programs falter.
Its three engagement models and its willingness to build custom suites are pitched directly at the "vendor flexibility is rare" complaint. And its GC Corporation backing gives it the capital of a large parent while keeping day-to-day operations local and nimble.
Made Scientific is a B2B, fee-for-service business. It earns revenue by providing development, manufacturing, fill-finish, testing, regulatory and training services to therapy developers - deepening relationships as a client's molecule moves from early development toward commercial supply.
It sits in a fast-growing corner of the market: outsourced manufacturing for cell and gene therapies. As more of these therapies win approval, the constraint shifts from can we make this to can we make it every time. The companies that solve reliable, scalable production will help decide who actually gets treated.
A cell therapy CDMO specializing in autologous and allogeneic therapies begins operations in New Jersey.
The company is supported by GC Corporation, with roughly $29.2 million in reported funding.
BioCentriq becomes Made Scientific, backed by a $12M facility investment; GMP services go live in Q2 2025.
The 60,000 sq. ft. facility anchors operations as a 12,000 sq. ft. GMP expansion is announced for commercial-scale work.
Ted Dolan (former COO of BioVectra) and Soyoung Park (GC Corporation) join the board to support scale-up and commercial readiness.
Chemical engineer (NJIT) and Cornell MBA with prior roles at Pfizer, Lonza, Alcami, Emergent BioSolutions and Resilience.
20+ years in biopharma manufacturing, with a background at Merck.
30+ years in pharma and biotech regulatory and compliance leadership.
15+ years in cell therapy manufacturing and process development.
15+ years scaling CDMO commercial operations.
South Korean pharma and biotech group providing capital and board representation.
It is a contract development and manufacturing organization (CDMO) that develops, manufactures, tests and releases cell therapy products for clinical and commercial supply.
Yes. It was formerly BioCentriq and rebranded to Made Scientific in March 2025.
It is backed by GC Corporation, a South Korean pharmaceutical and biotechnology group, which provides capital and board representation while the company retains operational autonomy.
Its headquarters and GMP manufacturing facility are in Princeton, New Jersey, USA.
Both autologous and allogeneic therapies across modalities including T cells, NK cells, HSCs, MSCs, iPSCs, TILs and exosomes.
Explore the company's work, news and cleanroom capabilities - and share this profile.